Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

C4591007 Clinical Trial Group, Emmanuel B Walter, Kawsar R Talaat, Charu Sabharwal, Alejandra Gurtman, Stephen Lockhart, Grant C Paulsen, Elizabeth D Barnett, Flor M Muñoz, Yvonne Maldonado, Barbara A Pahud, Joseph B Domachowske, Eric A F Simões, Uzma N Sarwar, Nicholas Kitchin, Luke Cunliffe, Pablo Rojo, Ernest Kuchar, Mika Rämet, Iona MunjalJohn L Perez, Robert W Frenck, Eleni Lagkadinou, Kena A Swanson, Hua Ma, Xia Xu, Kenneth Koury, Susan Mather, Todd J Belanger, David Cooper, Özlem Türeci, Philip R Dormitzer, Uğur Şahin, Kathrin U Jansen, William C Gruber

Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

Sormenjälki

Sukella tutkimusaiheisiin 'Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Medicine & Life Sciences